Post by Ambrosia Ventures

How much historical data is enough to benchmark a biotech licensing deal? For years, business development teams have relied on a relatively small number of comparable transactions to evaluate licensing opportunities. But today's market offers a different possibility. Ambrosia Ventures' Life Sciences Deal Calculator is built on a dataset of 3,062 verified biopharma transactions, giving teams access to a much broader view of how licensing deals have been structured across the industry. Why does that matter? Because no two deals are exactly the same. The more comparable transactions you can analyze, the easier it becomes to identify patterns in upfront payments, milestone structures, royalty ranges, and partner behavior. Good decisions aren't made from a single data point. They're made by recognizing trends across hundreds, if not thousands of transactions. As dealmaking becomes increasingly data-driven, organizations that benchmark against larger datasets may be better equipped to negotiate with confidence and identify opportunities others might overlook. Better data doesn't replace experience. It gives experienced teams a stronger foundation for making strategic decisions.